Celgene stays focused on protein homeostasis, backs Cleave’s $37M round to fuel early studies
Cleave Biosciences CEO Laura Shawver has built out her venture syndicate, adding cancer powerhouse Celgene to the mix and making key additions to the board as her biotech team preps for the next stage of clinical development. The expanded syndicate is contributing $37 million in fresh funds — bringing its total to $91 million — to complete Cleave’s navigation through a pair of early-stage cancer drug studies for its crucial lead program. And Celgene is demonstrating its renewed commitment to protein homeostasis, a field that has inspired a slate of deals in recent years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.